Drug Delivery最新文献_第4页

Correction notice. 更正通知。

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-06-18 DOI: 10.1080/10717544.2024.2339792

引用次数: 0

Nature's carriers: leveraging extracellular vesicles for targeted drug delivery. 大自然的载体：利用细胞外囊泡进行靶向给药。

IF 6 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-06-04 DOI: 10.1080/10717544.2024.2361165

Qi Chen, Yuyi Zheng, Xuhong Jiang, Yi Wang, Zhong Chen, Di Wu

{"title":"Nature's carriers: leveraging extracellular vesicles for targeted drug delivery.","authors":"Qi Chen, Yuyi Zheng, Xuhong Jiang, Yi Wang, Zhong Chen, Di Wu","doi":"10.1080/10717544.2024.2361165","DOIUrl":"10.1080/10717544.2024.2361165","url":null,"abstract":"With the rapid development of drug delivery systems, extracellular vesicles (EVs) have emerged as promising stars for improving targeting abilities and realizing effective delivery. Numerous studies have shown when compared to conventional strategies in targeted drug delivery (TDD), EVs-based strategies have several distinguished advantages besides targeting, such as participating in cell-to-cell communications and immune response, showing high biocompatibility and stability, penetrating through biological barriers, etc. In this review, we mainly focus on the mass production of EVs including the challenges and strategies for scaling up EVs production in a cost-effective and reproducible manner, the loading and active targeting methods, and examples of EVs as vehicles for TDD in consideration of potential safety and regulatory issues associated. We also conclude and discuss the rigor and reproducibility of EVs production, the current research status of the application of EVs-based strategies to targeted drug delivery, clinical conversion prospects, and existing chances and challenges.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2361165"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics. 认识胃肠道的生物屏障和病理生理特点，以设计和应用纳米疗法。

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1080/10717544.2024.2415580

Shan Li, Tianyu Wu, Jingfeng Wu, Wensheng Chen, Dinglin Zhang

{"title":"Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics.","authors":"Shan Li, Tianyu Wu, Jingfeng Wu, Wensheng Chen, Dinglin Zhang","doi":"10.1080/10717544.2024.2415580","DOIUrl":"https://doi.org/10.1080/10717544.2024.2415580","url":null,"abstract":"The gastrointestinal tract (GIT) is an important and complex system by which humans to digest food and absorb nutrients. The GIT is vulnerable to diseases, which may led to discomfort or even death in humans. Therapeutics for GIT disease treatment face multiple biological barriers, which significantly decrease the efficacy of therapeutics. Recognizing the biological barriers and pathophysiological characteristics of GIT may be helpful to design innovative therapeutics. Nanotherapeutics, which have special targeting and controlled therapeutic release profiles, have been widely used for the treatment of GIT diseases. Herein, we provide a comprehensive review of the biological barrier and pathophysiological characteristics of GIT, which may aid in the design of promising nanotherapeutics for GIT disease treatment. Furthermore, several typical diseases of the upper and lower digestive tracts, such as Helicobacter pylori infection and inflammatory bowel disease, were selected to investigate the application of nanotherapeutics for GIT disease treatment.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2415580"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple delivery strategies of nanocarriers for myocardial ischemia-reperfusion injury: current strategies and future prospective. 纳米载体治疗心肌缺血再灌注损伤的多种给药策略：当前策略与未来展望。

IF 6 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2023-12-26 DOI: 10.1080/10717544.2023.2298514

Shengnan Li, Fengmei Li, Yan Wang, Wenqun Li, Junyong Wu, Xiongbin Hu, Tiantian Tang, Xinyi Liu

{"title":"Multiple delivery strategies of nanocarriers for myocardial ischemia-reperfusion injury: current strategies and future prospective.","authors":"Shengnan Li, Fengmei Li, Yan Wang, Wenqun Li, Junyong Wu, Xiongbin Hu, Tiantian Tang, Xinyi Liu","doi":"10.1080/10717544.2023.2298514","DOIUrl":"10.1080/10717544.2023.2298514","url":null,"abstract":"Acute myocardial infarction, characterized by high morbidity and mortality, has now become a serious health hazard for human beings. Conventional surgical interventions to restore blood flow can rapidly relieve acute myocardial ischemia, but the ensuing myocardial ischemia-reperfusion injury (MI/RI) and subsequent heart failure have become medical challenges that researchers have been trying to overcome. The pathogenesis of MI/RI involves several mechanisms, including overproduction of reactive oxygen species, abnormal mitochondrial function, calcium overload, and other factors that induce cell death and inflammatory responses. These mechanisms have led to the exploration of antioxidant and inflammation-modulating therapies, as well as the development of myocardial protective factors and stem cell therapies. However, the short half-life, low bioavailability, and lack of targeting of these drugs that modulate these pathological mechanisms, combined with liver and spleen sequestration and continuous washout of blood flow from myocardial sites, severely compromise the expected efficacy of clinical drugs. To address these issues, employing conventional nanocarriers and integrating them with contemporary biomimetic nanocarriers, which rely on passive targeting and active targeting through precise modifications, can effectively prolong the duration of therapeutic agents within the body, enhance their bioavailability, and augment their retention at the injured myocardium. Consequently, these approaches significantly enhance therapeutic effectiveness while minimizing toxic side effects. This article reviews current drug delivery systems used for MI/RI, aiming to offer a fresh perspective on treating this disease.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2298514"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction. 撤回声明。

IF 6 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2023-01-18 DOI: 10.1080/10717544.2022.2157537

引用次数: 0

γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application. γ-环糊精水凝胶可持续释放柔红霉素，具有潜在的眼部应用前景。

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-06-20 DOI: 10.1080/10717544.2024.2361168

Jennifer Huling, Stefan Oschatz, Helge Lange, Katharina Anna Sterenczak, Thomas Stahnke, Jana Markhoff, Oliver Stachs, Steffen Möller, Nasrullah Undre, Anita Peil, Anselm Jünemann, Niels Grabow, Georg Fuellen, Thomas Eickner

{"title":"γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application.","authors":"Jennifer Huling, Stefan Oschatz, Helge Lange, Katharina Anna Sterenczak, Thomas Stahnke, Jana Markhoff, Oliver Stachs, Steffen Möller, Nasrullah Undre, Anita Peil, Anselm Jünemann, Niels Grabow, Georg Fuellen, Thomas Eickner","doi":"10.1080/10717544.2024.2361168","DOIUrl":"10.1080/10717544.2024.2361168","url":null,"abstract":"Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous in silico drug screening and in vitro testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2361168"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer. 撤回声明：用还原石墨烯纳米复合材料递送双抗癌药物治疗肝癌的聚合合成平台

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-06-25 DOI: 10.1080/10717544.2024.2368971

引用次数: 0

Advances in polymeric nano-delivery systems targeting hair follicles for the treatment of acne. 针对毛囊的聚合物纳米给药系统在治疗痤疮方面的进展。

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-07-02 DOI: 10.1080/10717544.2024.2372269

Yujing Lei, Wanting Jiang, Cheng Peng, Donghai Wu, Jing Wu, Yiling Xu, Hong Yan, Xinhua Xia

引用次数: 0

Correction. 更正。

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-07-02 DOI: 10.1080/10717544.2024.2374134

引用次数: 0

Multi-shell gold nanoparticles functionalized with methotrexate: a novel nanotherapeutic approach for improved antitumoral and antioxidant activity and enhanced biocompatibility. 甲氨蝶呤功能化多壳金纳米粒子：一种提高抗肿瘤和抗氧化活性以及生物相容性的新型纳米治疗方法。

IF 6.5 2区医学

Drug Delivery Pub Date : 2024-12-01 Epub Date: 2024-08-17 DOI: 10.1080/10717544.2024.2388624

Denisse-Iulia Bostiog, Natalia Simionescu, Adina Coroaba, Ioana C Marinas, Mariana C Chifiriuc, Gratiela Gradisteanu Pircalabioru, Stelian S Maier, Mariana Pinteala

{"title":"Multi-shell gold nanoparticles functionalized with methotrexate: a novel nanotherapeutic approach for improved antitumoral and antioxidant activity and enhanced biocompatibility.","authors":"Denisse-Iulia Bostiog, Natalia Simionescu, Adina Coroaba, Ioana C Marinas, Mariana C Chifiriuc, Gratiela Gradisteanu Pircalabioru, Stelian S Maier, Mariana Pinteala","doi":"10.1080/10717544.2024.2388624","DOIUrl":"10.1080/10717544.2024.2388624","url":null,"abstract":"Methotrexate (MTX) is a folic acid antagonist routinely used in cancer treatment, characterized by poor water solubility and low skin permeability. These issues could be mitigated by using drug delivery systems, such as functionalized gold nanoparticles (AuNPs), known for their versatility and unique properties. This study aimed to develop multi-shell AuNPs functionalized with MTX for the improvement of MTX antitumoral, antioxidant, and biocompatibility features. Stable phosphine-coated AuNPs were synthesized and functionalized with tailored polyethylene glycol (PEG) and short-branched polyethyleneimine (PEI) moieties, followed by MTX covalent binding. Physicochemical characterization by UV-vis and Fourier-transform infrared spectroscopy (FTIR) spectroscopy, dynamic light scattering (DLS), scanning transmission electron microscopy (STEM), and X-ray photoelectron spectroscopy (XPS) confirmed the synthesis at each step. The antioxidant activity of functionalized AuNPs was determined using DPPH radical scavenging assay, ferric ions' reducing antioxidant power (FRAP), and cupric reducing antioxidant capacity (CUPRAC) assays. Biocompatibility and cytotoxicity were assessed using MTT and LDH assays on HaCaT human keratinocytes and CAL27 squamous cell carcinoma. MTX functionalized AuNPs demonstrated enhanced antioxidant activity and a pronounced cytotoxic effect on the tumoral cells compared to their individual components, highlighting their potential for improving cancer therapy.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2388624"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0